Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$76.2BCash on Hand
CF+ Cash Runway
Follow RDY by emailGet an email when RDY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RDY, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Regulatory USFDA classified the inspection of Dr. Reddy's formulations facility FTO-3 in Bachupally, Hyderabad as Voluntary Action Indicated (VAI) and officially closed it under 21 CFR 20.64(d)(3). The notice was dated November 14, 2026. Form 6-K · SEC filing · Press release
Nov 10, 2026 ·
Dr. Reddy's management will attend an in-person group meeting hosted by JM Financial in Mumbai on November 16, 2026, and an in-person group meeting hosted by Investec in London on November 17 and 18, 2026. The schedule is subject to change. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Regulatory Dr. Reddy's received ANVISA marketing authorization in Brazil for generic semaglutide injection for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise. The launch is planned with Aché. Form 6-K · SEC filing · Press release
Oct 29, 2026 ·
Regulatory USFDA classified the Pre-Approval Inspection and GMP inspection at the FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh as Voluntary Action Indicated (VAI) and officially closed the inspection. Form 6-K · SEC filing · Press release
Oct 29, 2026 ·
Earnings Dr. Reddy's furnished the transcript of its October 23, 2026 earnings call for the quarter and half year ended September 30, 2026, posted on its website. The filing contains no financial figures. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Earnings Dr. Reddy's filed the auditors' limited review reports on its unaudited consolidated and standalone results for the quarter and half year ended September 30, 2026, dated October 23, 2026. The filing contains no figures for revenue or profit. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Earnings Dr. Reddy's furnished an audio and video link to its October 23, 2026 earnings call on unaudited results for the quarter and half year ended September 30, 2026. The filing contains no financial figures. Form 6-K · SEC filing · Press release
Oct 23, 2026 ·
Earnings Dr. Reddy's filed its quarterly report for the three and six months ended September 30, 2026, with Deloitte Haskins & Sells LLP reporting no material modifications needed to the interim financial statements under IFRS Accounting Standards. The provided text does not include the reported figures. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2016 · Phase 2 · Results Expected · Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not RDY's own candidates): Pembrolizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
RDY holds $76.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Share count 834,656,970 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full RDY picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RDY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.